ERBB2 and breast carcinoma: Their study demonstrated that the addition of IL-21 significantly increased strong cytotoxicity against trastuzumab-resistant breast cancer cells with the synthesis and secretion of IFN-γ and IL-2, after combining HER2-targeted CAR-T cells with trastuzumab-resistant HCC1954 and BT474 cells (107).